Abstract: Fusion of the HIV envelope with the target cell membrane is a critical step of the HIV entry into the target cell. Several peptides based on the C-region of HIV gp41 have been used in clinical trials as possible HIV fusion inhibitors. Among these are T-1249 and T-20 (also known as enfurvitide). Despite recent works, a detailed molecular picture of the inhibitory mechanism of these molecules is still lacking. These peptides are usually depicted as α-helices by analogy with the structure of the sequence of the gp41 protein with which they are homologous. However, structures like these would be highly unstable in solution and thus would not explain, by themselves, the ability that the two fusion inhibitors have to become solvated by water and also interact effectively with cell membranes. To this effect, extensive molecular dynamics simulations were carried out to investigate the structure and conformational behavior of T-1249 and T-20 in water, as well as shorter homologous peptides CTP and 3f5, which show no inhibitory action. We found that the studied inhibitors have no stable structure in solution in the time scale studied. Additionally, the solvent accessible area varies significantly during the simulation. Our findings suggest that these peptides may assume not only one, but several possible sets of structures in solution, some of which more adequate to interact with the solvent, whereas others might be better suited to interact with cell membranes. Interestingly, and in accordance with published experimental studies, we verified that T-1249 displays considerably larger α-helical structure than T-20. Taking into account a recent study with design peptides with increased helicity, it is possible that this feature may be related to the increased inhibiting efficiency of T-1249 relative to that of T-20.
INTRODUCTION
Membrane fusion between enveloped viruses and host cell membranes is an obligatory process of viral infection that is mediated by viral glycoproteins [1] [2] [3] . The initial steps of HIV-1 infection of a target cell (binding of the virus to the target cell and fusion of the membranes of both) are mediated by the viral envelope glycoprotein complex formed by the transmembrane protein gp41 (responsible for membrane fusion), and the surface protein gp120 (responsible for host recognition), bound to the external domain of gp41 [4] . Entry of the HIV into a target cell is performed in three steps: (i) binding of the viral gp120 to the target cell surface protein CD4 (a protein present in helper T-cells and involved in the immunologic response), a critical step for the attachment of the virus particle to the target cell [5] ; (ii) this process changes the conformation of gp120 enabling this protein to bind to yet another receptor on the immune system cell's surface, typically CCR5 [6] or CXCR4 [7] ; and (iii) gp41-mediated membrane fusion [4] . The previous processes, mediated by gp120, result in a conformational change in gp41, which exposes a fusion peptide and allows it to insert into the membrane of the target cell, hence leading to the fusion of the two membranes and the entry of the viral components into the target cell [4, 8] . Several peptides based on the C-region of the HIV gp41 have been used in clinical trials as possible HIV fusion inhibitors [reviewed in [9] ]. Among these are T-1249 [10] and T-20, also known as enfurvitide [11] [12] [13] (Figure 1 ).
T-20 is a synthetic 36-amino-acid peptide whose sequence is homologous to the C-terminal of HR2 (Heptad Repeat 2) of gp41 [11] . This first generation peptide is currently one of the more advanced clinical drugs for inhibiting HIV-1 entry and has received fast Food and Drugs Administration (FDA) approval [14, 15] . Despite T-20's effectiveness it has, already, encountered some resistant strains of HIV [12, 15] .
T-1249 is a synthetic 39-amino-acid peptide composed of sequences derived from HIV-1, HIV-2, and Simian immunodeficiency virus (SIV) [10] . This fusion inhibitor is in phase II clinical trials, and both phase I and II clinical trials have shown that it is a stronger inhibitor of HIV entry than T-20 and it retains function against T-20 resistant strains [10, 12, 13] . Despite recent works, a detailed molecular picture of the inhibitory mechanism promoted by these molecules is still lacking. Working models for their mechanisms of action, based mainly on fluorescence spectroscopy data, were presented in [16] (T-20) and [17] (T-1249). Both schemes rely on the experimentally verified efficient partition of the two peptides to zwitterionic bilayers, and differences between them arise from the possibility of T-1249 (but not T-20) adsorbing to cholesterol-rich membranes, which might be the main cause of its improved efficiency (see Ref. 17 for a detailed discussion).
T-20 and T-1249 are usually depicted, at least partly, as α-helices by analogy with the structure of the sequences with which they are homologous. However, this representation is most probably not accurate for an aqueous environment. The presence of a large number of hydrophobic amino-acid residues in the sequence of both peptides ( Figure 1 ) would cause them, in solution, to fold in order to form more globular structures that would improve their solubility. This fact has been observed for both T-20 and T-1249 by CD spectroscopy [17] . These peptides also have the ability to interact with/partition to cell membranes and their mode of action depends partly on that property. However, both fusion inhibitors in this study are endovenous drugs and, as such, knowledge of their structure and behavior in solution would help our understanding of their mode of action.
In this work, we study the structure and behavior of these two peptides in solution using MD simulations in the 100 ns time scale. This was done also with the aim of determining models of the two fusion inhibitors that could be used to study their interaction with model membranes. Two smaller model peptides, 3f5 and CTP (Figure 1 ), homologous with both fusion inhibitors in study, were also investigated with the same approach. The use of smaller peptides allows for longer simulated time ranges and hence for the study of longer time scale properties. In this way, 3f5 and CTP were studied to determine whether the studied 100-ns time range was sufficient or if there was the need to extend the study to longer time ranges.
METHODS
Initial models of the four peptides (α-helices) were built with the Arguslab 4.01 package [18] and solvated in cubic simulation boxes with SPC water [19] , with dimensions and water content proportional to the size of the peptide in question (the distance between each molecule and the box walls is 0.5 nm): 3f5 was simulated in a box of 3.45 × 3.45 × 3.45 nm 3 [20, 21] . The force field used to describe the peptide interactions was the Gromos96 43a1 force field [22, 23] . Prior to the MD simulation, the four systems underwent a steepest-descent energy minimization of the structure, followed by a small MD run with restraints in the peptide atoms positions to properly allow the solvent molecules to adjust/relax around the peptide. Restraints were subsequently removed, and extensive (100 ns) molecular dynamics simulations were then performed under constant number of particles, pressure (1 bar), and temperature (300 K), and using periodic boundary conditions. Pressure and temperature control was carried out using the weakcoupling Berendsen schemes [24] , with coupling times of 1.0 and 0.1 ps, respectively. Isotropic pressure coupling was used. All bonds were constrained to their equilibrium values, using the SETTLE algorithm [25] for water and the LINCS algorithm [26] for all other bonds. This approach allowed the use of a time-step of 2 fs. Cutoffs of 1 nm were used in the treatment of electrostatic interactions. Although this is not the most accurate treatment for this type of long range interactions, it allowed the study of longer time scales in a more reasonable computer simulation time. The monitored parameters include the root mean square deviation (RMSD) relative to the initial conformation, radius of gyration (RG), secondary structure (SS), and solvent accessible surface (SAS). RMSD and RG were calculated using Gromacs 3.3.1 analysis packages [20, 21] , whereas SS and SAS were computed using the DSSP program [27] .
RESULTS AND DISCUSSION
In the time scale studied, all the peptides evolve roughly in a similar fashion from the α-helix initial model to a more or less globular flexible structure. This evolution occurs in two stages. In the first stage (t < 25 ns), the peptides rapidly change in conformation. This is clearly shown in the time dependence of the RMSDs which have a larger variation in this time frame (Figure 2) , thus suggesting this rapid structural change. The RGs, as a measure of the size of the peptide, also have a substantial decrease in this first stage (Figure 3 ), thus reflecting a change from an α-helix to a more globular structure. All peptides evolve away from the initial models into globular structures (see Figure 4 for typical snapshots of these) that are more capable of protecting the more hydrophobic residues from the solvent, therefore stabilizing the structure in solution.
Comparing T-20 with T-1249, it can be seen from Figure 4 that the changes in secondary structure away from the α-helical initial model are especially rapid in the former. This is a first indication of the experimentally verified [17] increased helicity of T-1249 relative to T-20 (but see also below).
This first stage of the folding of these peptides is followed by a second stage (t > ∼25) of smoother evolution in which they adopt a number of different globular flexible structures that interchange between one another (see snapshots and SS evolution in Figure 4 ). This is also apparent in the time variations of the RMSD (Figure 2 (Figure 2 ), and it also shows a considerable helical content. This different behavior may be related to the additional six residues located in its C-terminal (Figure 1 ) that may be helping the its structure to stabilize and form the α-helix. By comparison, 3f5, which does not possess these residues, behaves in much the same way as the other peptides, with the exception of the T-1249's N -terminus behavior that also shows moderate helical content. This behavior seems to be important, since it was observed in a recent report that helix-stabilized HIV-1 fusion inhibitor peptides were more active than T-20 -as much as 3600-fold [28] . However, further studies with a wider variety of peptides would be required to better understand these results. In particular, the absence of inhibitory activity in CTP in spite of the stability of its helical structure (and 14-amino-acid homology with T-20), suggests that this is not the single factor influencing the peptide's inhibitory activity.
To investigate if the lack of a stable structure for the fusion inhibitors and 3f5 in our simulations was due to a limitation in the time scale simulated, we carried out longer simulations of 3f5 (500 ns). No change in the described structural pattern was apparent, ruling out time scale problems in this matter.
Both the SAS of each residue ( Figure 5 ) and the SS of T-20 and T-1249 (Figure 4 ) vary significantly during the simulation time. The average content of α-helix for the last 75 ns of each simulation of these peptides was calculated and was found to be negligible for T-20 and 16.4% for T-1249 in qualitative accordance with experimental data obtained by Veiga and coworkers by CD spectroscopy measurements [17] . These authors measured 8 and 30% of α-helical content in buffer, for T-20 and T-1249, respectively. The higher results obtained in their study may be related to the intrinsic differences between the recovery of secondary structure from CD spectra (only three types of structures are recognized [29] ) and the SS analysis of our atomistic MD simulations (which differentiates 8 types of secondary structures [27] ). An alternative explanation is that the studied time scale is insufficient for secondary structure analysis, and that structural changes may occur in longer time scales. 
CONCLUSIONS
Our results show that the studied peptides have no stable structure in solution in the studied time scale, and also that these peptides, especially the fusion inhibitors, may assume not only one, but several possible sets of structures in solution, some of which are probably extensively solvated, whereas others might be better suited to interact with cell or model membranes. These properties suit the inhibitor peptides to the function they were designed for, as they should be sufficiently soluble, but still capable of interacting, adsorbing and/or incorporating into lipid membranes. Molecular models of the interactions of both T-20 and T-1249 with model membranes were proposed by Veiga and coworkers [16, 17] . Their results show that both T-20 and T-1249 are able to partition to the host membrane. Translocation should be impossible because of charge effects. Furthermore, T-1249 should be able to interact more strongly with cholesterol-rich surfaces, such as lipid rafts, where HIV-1 receptor CD4 and coreceptors CXCR4/CCR5 are considered to be located [30] (this may account for its higher efficiency in inhibiting the fusion of the virus, as suggested in [17] ). To evaluate these hypotheses, simulations of the interactions of the fusion inhibitor peptides with model membranes of varying composition are underway. One of the main goals of the present study was to obtain realistic models of the inhibitory peptides in aqueous solution that could be used as starting points for simulations of the peptides in presence of model membranes. In this way, T-1249 is currently being simulated in the presence of a 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine bilayer. Using the final structure of the peptide in this study as starting point, located in water ∼2 nm above the lipid/water interface, a preliminary observation of the trajectory under calculation points to a rapid adsorption of the peptide to the surface of the model membrane (t < 4-5 ns; data not shown). The possibility of effective peptide incorporation for longer times is being investigated.
